These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 9562693)

  • 1. Whole-killed gp120-depleted HIV-1 antigen in a murine model for prophylactic vaccination.
    Lanza P; Moss RB; Giermakowska W; Hancock RB; Richieri SP; Theofa G; Jensen FC; Salk PL; Carlo DJ
    Vaccine; 1998 Apr; 16(7):727-31. PubMed ID: 9562693
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Human immunodeficiency virus (HIV)-specific immune responses are generated with the simultaneous vaccination of a gp120-depleted, whole-killed HIV-1 immunogen with cytosine-phosphorothioate-guanine dinucleotide immunostimulatory sequences of DNA.
    Moss RB; Diveley J; Jensen FC; Gouveia E; Carlo DJ
    J Hum Virol; 2001; 4(1):39-43. PubMed ID: 11213932
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunization with gp120-depleted whole killed HIV immunogen and a second-generation CpG DNA elicits strong HIV-specific responses in mice.
    Trabattoni D; Clivio A; Bray DH; Bhagat L; Beltrami S; Maffeis G; Cesana E; Lowry P; Lissoni F; Kandimalla ER; Sullivan T; Agrawal S; Bartholomew R; Clerici M
    Vaccine; 2006 Feb; 24(9):1470-7. PubMed ID: 16221513
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vaccination with gp120-depleted HIV-1 plus immunostimulatory CpG oligodeoxynucleotides in incomplete Freund's adjuvant stimulates cellular and humoral immunity in rhesus macaques.
    Silvera P; Savary JR; Livingston V; White J; Manson KH; Wyand MH; Salk PL; Moss RB; Lewis MG
    Vaccine; 2004 Dec; 23(6):827-39. PubMed ID: 15542208
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cross-clade immune responses after immunization with a whole-killed gp120-depleted human immunodeficiency virus type-1 immunogen in incomplete Freund's adjuvant (HIV-1 immunogen, REMUNE) in human immunodeficiency virus type-1 seropositive subjects.
    Moss RB; Giermakowska W; Lanza P; Turner JL; Wallace MR; Jensen FC; Theofan G; Richieri SP; Carlo DJ
    Viral Immunol; 1997; 10(4):221-8. PubMed ID: 9473153
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro immune function after vaccination with an inactivated, gp120-depleted HIV-1 antigen with immunostimulatory oligodeoxynucleotides.
    Moss RB; Diveley J; Jensen F; Carlo DJ
    Vaccine; 2000 Jan; 18(11-12):1081-7. PubMed ID: 10590329
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HIV-Specific CD4(+) and CD8(+) immune responses are generated with a gp120-depleted, whole-killed HIV-1 immunogen with CpG immunostimulatory sequences of DNA.
    Moss RB; Diveley J; Jensen FC; Gouveia E; Savary J; Carlo DJ
    J Interferon Cytokine Res; 2000 Dec; 20(12):1131-7. PubMed ID: 11152580
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Maternal and newborn immunization with a human immunodeficiency virus-1 immunogen in a rodent model.
    Moss RB; Savary JR; Diveley JP; Jensen F; Carlo DJ
    Immunology; 2002 Aug; 106(4):549-53. PubMed ID: 12153518
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro p24 antigen-stimulated lymphocyte proliferation and beta-chemokine production in human immunodeficiency virus type 1 (HIV-1)-seropositive subjects after immunization with an inactivated gp120-depleted HIV-1 immunogen (Remune).
    Moss RB; Wallace MR; Lanza P; Giermakowska W; Jensen FC; Theofan G; Chamberlin C; Richieri SP; Carlo DJ
    Clin Diagn Lab Immunol; 1998 May; 5(3):308-12. PubMed ID: 9605982
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adsorption to aluminum hydroxide promotes the activity of IL-12 as an adjuvant for antibody as well as type 1 cytokine responses to HIV-1 gp120.
    Jankovic D; Caspar P; Zweig M; Garcia-Moll M; Showalter SD; Vogel FR; Sher A
    J Immunol; 1997 Sep; 159(5):2409-17. PubMed ID: 9278332
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of immunization with inactivated gp120-depleted human immunodeficiency virus type 1 (HIV-1) immunogen on HIV-1 immunity, viral DNA, and percentage of CD4 cells.
    Trauger RJ; Ferre F; Daigle AE; Jensen FC; Moss RB; Mueller SH; Richieri SP; Slade HB; Carlo DJ
    J Infect Dis; 1994 Jun; 169(6):1256-64. PubMed ID: 7910836
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A qualitative progression in HIV type 1 glycoprotein 120-specific cytotoxic cellular and humoral immune responses in mice receiving a DNA-based glycoprotein 120 vaccine.
    Fuller DH; Haynes JR
    AIDS Res Hum Retroviruses; 1994 Nov; 10(11):1433-41. PubMed ID: 7888198
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CD8+ T-cell-mediated cross-clade protection in the genital tract following intranasal immunization with inactivated human immunodeficiency virus antigen plus CpG oligodeoxynucleotides.
    Jiang JQ; Patrick A; Moss RB; Rosenthal KL
    J Virol; 2005 Jan; 79(1):393-400. PubMed ID: 15596832
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In interleukin-4-deficient mice, alum not only generates T helper 1 responses equivalent to freund's complete adjuvant, but continues to induce T helper 2 cytokine production.
    Brewer JM; Conacher M; Satoskar A; Bluethmann H; Alexander J
    Eur J Immunol; 1996 Sep; 26(9):2062-6. PubMed ID: 8814247
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficient mucosal delivery of the HIV-1 Tat protein using the synthetic lipopeptide MALP-2 as adjuvant.
    Borsutzky S; Fiorelli V; Ebensen T; Tripiciano A; Rharbaoui F; Scoglio A; Link C; Nappi F; Morr M; Buttó S; Cafaro A; Mühlradt PF; Ensoli B; Guzmán CA
    Eur J Immunol; 2003 Jun; 33(6):1548-56. PubMed ID: 12778472
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mucosal immunity to HIV-1: systemic and vaginal antibody responses after intranasal immunization with the HIV-1 C4/V3 peptide T1SP10 MN(A).
    Staats HF; Nichols WG; Palker TJ
    J Immunol; 1996 Jul; 157(1):462-72. PubMed ID: 8683152
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mucosal immunization with inactivated human immunodeficiency virus plus CpG oligodeoxynucleotides induces genital immune responses and protection against intravaginal challenge.
    Dumais N; Patrick A; Moss RB; Davis HL; Rosenthal KL
    J Infect Dis; 2002 Oct; 186(8):1098-105. PubMed ID: 12355360
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and immunogenicity of a gp120-depleted, inactivated HIV-1 immunogen: results of a double-blind, adjuvant controlled trial.
    Trauger RJ; Daigle AE; Giermakowska W; Moss RB; Jensen F; Carlo DJ
    J Acquir Immune Defic Syndr Hum Retrovirol; 1995; 10 Suppl 2():S74-82. PubMed ID: 7552517
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Down-regulation of Th1-mediated pathology in experimental arthritis by stimulation of the Th2 arm of the immune response.
    Mauri C; Feldmann M; Williams RO
    Arthritis Rheum; 2003 Mar; 48(3):839-45. PubMed ID: 12632440
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Macrophage inflammatory protein-1alpha (MIP-1alpha) expression plasmid enhances DNA vaccine-induced immune response against HIV-1.
    Lu Y; Xin KQ; Hamajima K; Tsuji T; Aoki I; Yang J; Sasaki S; Fukushima J; Yoshimura T; Toda S; Okada E; Okuda K
    Clin Exp Immunol; 1999 Feb; 115(2):335-41. PubMed ID: 9933462
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.